首页 | 本学科首页   官方微博 | 高级检索  
     


New generation drugs for treatment of multiple myeloma
Affiliation:1. Acucela Inc., 818 Stewart St, Suite 1110, Seattle, WA 9810, USA;2. Halloran Consulting Group, 266 Summer St, Boston, MA 02210, USA;1. Department of Pharmacology and Clinical Pharmacology, and Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, New Zealand;2. Institute of Biomedicine, Faculty of Health Sciences, The University of Eastern Finland, Finland;3. Department of Radiology, The University of Cambridge, UK;4. ARC Centre for Innovation in Biomedical Imaging Technology, Centre for Advanced Imaging, The University of Queensland, Australia
Abstract:
Keywords:Aspirin (PubChem CID: 2244)  Bortezomib (PubChem CID: 387447)  Carfilzomib (PubChem CID: 11556711)  Cyclophosphamide (PubChem CID: 2907)  Daratumumab/Anti-CD38 (PubChem SID: 378174561)  Dexamethasone (PubChem CID: 5743)  Histone deacetylase (HDAC) inhibitors (PubChem CID: 10095659)  Ixazomib (PubChem CID: 772)  Lenalidomide (PubChem CID: 216326)  Low molecular weight heparin (PubChem CID: 772)  Panobinostat (PubChem CID: 6918837)  Pomalidomide (PubChem CID: 134780)  Thalidomide (PubChem CID: 5426)
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号